GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of non-peptide: the version I wish someone had shown me in week 1 — 36 comments in the full submission. View in context.
831
c/orforglipron·submitted 1 year ago by u/lukas_delgado

non-peptide: the version I wish someone had shown me in week 1

Discussionbranch of 7 comments

non-peptide: the version I wish someone had shown me in week 1. Posting the boring middle of the process, because the internet is full of the start and the end and nothing else. Spent an evening reading about small-molecule agonism at a peptide receptor. Genuinely interesting engineering. Daily rather than weekly…

Read the full submission and all 36 comments →

This branch

7 comments, started 1 year ago
u/farid_kuipers100 points·1 year ago

Because it is not a peptide, it is not subject to the same degradation pathways, does not require the absorption enhancers used for oral peptides, and can be formulated as a conventional tablet.

replysharereportpermalink
u/trialwatch_theotrial nerd31 points·1 year ago

Compared milligram figures across two completely different molecule classes in a comment. Deserved the correction.

replysharereportpermalink
u/preservative_free_p10 points·1 year ago

Compared milligram figures across two completely different molecule classes in a comment.

Disagreeing with this bit: daily dosing is a different adherence problem, not a better one.

replysharereportpermalink
u/kenji_kimani2 points·1 year ago·edited

nothing containing this is approved anywhere and research material is not for human use

replysharereportpermalink
u/hamza_weiss9 points·1 year ago

It is a non-peptide small-molecule agonist at the GLP-1 receptor. That is a substantial medicinal chemistry achievement: getting a small molecule to activate a receptor evolved for a peptide ligand.

replysharereportpermalink
u/marit_sandvik3 points·1 year ago

phase 3 is where the comparison becomes fair

replysharereportpermalink
u/whois_wanda27 points·1 year ago

the boards keep comparing it to injectables at matched doses, which is meaningless

replysharereportpermalink

← back to the whole thread

About c/orforglipron

The small-molecule oral: why a non-peptide agonist escapes the absorption problems of oral semaglutide, what the ATTAIN and ACHIEVE readouts showed, and what a pill with no refrigeration requirement would do to the entire supply conversation this site is built around.

21kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/orforglipron rules
  1. Small molecule, not a peptide. Purity discussion here is a different problem.
  2. Cite ATTAIN/ACHIEVE arms specifically when quoting numbers.
  3. Availability speculation must be flaired Speculation.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.